Healthium Medtech Ltd. is the largest homegrown surgical suture and needles manufacturer. The company is the largest manufacturer of surgical needles globally by volume.
Currently, more than 7 marquee acquirers are competing to buy this gem.
What is driving the buzz around the potential acquisition of Healthium Medtech?
To answer this question, lets touch upon company’s history and background
For starters, 1 in 5 surgeries performed globally uses Healthium products. Simply saying, the company enjoys 20% global market share.
The company was set up as Sutures India in 1992 by LG Chandrashekhar and S Subramanian in Bangalore. Currently, they manufacture and sell a broad range of medical devices and consumable products like sutures, needles, surgical gloves, etc., for corporate and public hospitals, nursing homes, and other institutions. Catering to 90+ countries.
The company also provides customized OEM and private label services. As of 2021, the company catered to 40,000 surgeons across 18,000+ hospitals pan India, representing 40% of surgeons and 52% of hospitals in the country.
Clinisupplies, the UK division of Healthium, is a leading medical device player in the UK, particularly known for urology products. As of today, Healthium Medtech has 85+ registered patents across the US, Europe, and India.
In terms of products, it is the largest surgical needle manufacturer by volume worldwide and ranks 4th in manufacturing sutures globally. The company has a presence in 90+ countries currently.
We believe that the above section must have given you a satisfactory answer.
Who are these marquee investors looking to buy Healthium?
In January, it was reported that Apax Partners started discussions to sell Healthium Medtech and was looking for buyers.
Currently, the following known institutions are in the race to buy the company:
Now lets answer an exciting question, how much are these investors willing to pay?
Today Healthium Medtech is valued at ~Rs. 6,500 – 7,000 cr. making it one of the most contentious deals of the year.
Who will benefit?
Reading the last section must have given you an idea that currently, the company is owned by a renowned PE firm, Apex Partners who are going to be the sole beneficiaries of this deal.
It was in 2018, the British PE firm bought 99.8% of Healtium Pvt. Ltd. from existing shareholders including TPG Group, CX Partners, and founding promoters. The deal was valued at Rs. 1,950 cr.
In short, Apex Partners are fancying a 3.0-3.5x about 5 years time. That’s a neat profit isn’t it?
Unsuccessful IPO Attempt:
In 2021, Healthium received approval from SEBI for its IPO to raise Rs. 1,500 cr. However, the offering failed to garner much attention and IPO plans were squashed.
Fin Meme of the Week
Bidding adieu on a lighter note
